摘要
抗肝纤维化是中医药防治病毒性肝炎特色优势的重要体现。《2016-2021年全球卫生部门病毒性肝炎战略》、《中国病毒性肝炎防治规划(2017-2020)》的发布为中医药防治肝纤维化带来机遇。如何提高肝纤维化的疗效、研发更多抗肝纤维化的有效中药新药是新形势下中医药防治肝纤维化研究的挑战。以提高临床疗效为目的,从肝纤维化发生发展的不同阶段着手,发挥中医辨证论治的优势,早期干预,并联合精准医学、中医特色慢病管理等手段开展临床与基础研究,进一步建立并推广应用中医药防治肝纤维化的临床诊疗指南及中医药防治肝纤维化的中医特色慢病管理指南是未来中医药防治肝纤维化研究的重要内容。
The prevention and treatment of liver fibrosis is an important embodiment of the characteristic advantage of traditional Chinese medicine（TCM） in the prevention and treatment of viral hepatitis.The release of Global Health Sector Strategy on Viral Hepatitis,2016-2021 and Viral Hepatitis Prevention and Control Plan of China（2017-2020） brings opportunities to TCM prevention and treatment of liver fibrosis.There are still challenges in the research on TCM prevention and treatment of liver fibrosis,including how to improve the outcome of liver fibrosis and the research and development of more effective TCM new drugs for liver fibrosis.With the purpose of improving the clinical effect,we will start from the different stages of the development and progression of liver fibrosis,use the advantages of TCM syndrome differentiation-based treatment,provide early intervention,conduct clinical and basic research with the combination of precision medicine and TCM management of chronic diseases,and further establish and promote the application of the guidelines for clinical diagnosis and treatment of liver fibrosis and the TCM management guidelines for chronic diseases,which are the important contents of TCM prevention and treatment of liver fibrosis in future.
作者
池晓玲
萧焕明
CHI Xiaoling;XIAO Huanming.(The Liver Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510100, China)
出处
《临床肝胆病杂志》
CAS
北大核心
2018年第4期694-697,共4页
Journal of Clinical Hepatology
关键词
肝硬化
肝炎
病毒性
人
中医疗法
liver cirrhosis
hepatitis,viral,human
TCM therapy
